It is noted that UBR5 can upregulate PDL1 transcription to promote tumor immune evasion and that restoration of PD-L1 expression in UBR5-deficient tumor decreases T cell infiltration and restores malignancy, as was indirectly proven by the combination therapy targeting both UBR5 and PD-L1 in the TNBC mouse model. Here, UBR5 is linked to neoplasm.